Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 30(1); 2006 > Article
Original Article The long term effects of rosiglitazone on serum lipid concentration and body weight.
Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Yu Mie Rhee, Chul Woo Ahn, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee, Bong Soo Cha
Diabetes & Metabolism Journal 2006;30(1):17-24
DOI: https://doi.org/10.4093/jkda.2006.30.1.17
Published online: January 1, 2006
  • 2,155 Views
  • 17 Download
  • 0 Crossref
  • 0 Scopus
1Department of Internal Medicine, Yonsei University College of Medicine.
2Department of Internal Medicine, College of Medicine, Pochon CHA University.
3Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine.

BACKGROUND
Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentration and low density lipoprotein (LDL) particle size, it has adverse effects on the increment of total cholesterol (TC) and LDL cholesterol (LDL-C), and body weight in some studies. Such adverse effects of rosiglitazone on the serum lipid profiles and body weight seem to be attributed to the fact that most studies with rosiglitazone are limited to a short period of follow up. The aim of this study was to evaluate the long term effects of rosiglitazone on the serum lipid levels and body weight. MATERIALS AND METHODS: We prospectively evaluated fasting serum glucose, HbA1c, TC, LDL-C, triglyceride, HDL-C and body weight at baseline and every three months after rosiglitazone usage (4mg/d) in 202 type 2 diabetic patients. RESULTS: TC levels had increased maximally at 3 months and thereafter decreased, but were significantly higher at 18 months than those at baseline. LDL-C levels from the first 3 months to 12 months were significantly higher than those at baseline, but after 15 months, LDL-C concentration was not significantly different from the basal LDL-C concentration. HDL-C levels had increased after first 3 months and the increment of HDL-C concentration were maintained. The increment of HDL-C was more prominent in patients with low basal HDL-C concentration than in patients with high basal HDL-C concentration. Body weight from 3 months to 18 months were higher than that at baseline, but after 3 months, body weight did not increase furthermore significantly. CONCLUSIONS: The adverse effects on lipid concentration and body weight of rosiglitazone may attenuate after long term usage of rosiglitazone.

  • Cite
    CITE
    export Copy
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    The long term effects of rosiglitazone on serum lipid concentration and body weight.
    Korean Diabetes J. 2006;30(1):17-24.   Published online January 1, 2006
    Close
Related articles
Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES, Rhee YM, Ahn CW, Lim SK, Kim KR, Lee HC, Cha BS. The long term effects of rosiglitazone on serum lipid concentration and body weight.. Diabetes Metab J. 2006;30(1):17-24.
DOI: https://doi.org/10.4093/jkda.2006.30.1.17.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer